172 related articles for article (PubMed ID: 20732652)
1. Targeting the B cell in rheumatoid arthritis.
Cohen SB
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):553-63. PubMed ID: 20732652
[TBL] [Abstract][Full Text] [Related]
2. B-cell therapies in established rheumatoid arthritis.
Leandro MJ; Becerra-Fernandez E
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
[TBL] [Abstract][Full Text] [Related]
3. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
De Vita S; Quartuccio L
Autoimmun Rev; 2006 Aug; 5(7):443-8. PubMed ID: 16920570
[TBL] [Abstract][Full Text] [Related]
4. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
5. [Safety of rituximab in patients with rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab: a step forward in the evolution of B-cell therapy.
Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?
Benucci M; Manfredi M; Puttini PS; Atzeni F
Autoimmun Rev; 2010 Oct; 9(12):801-3. PubMed ID: 20656069
[TBL] [Abstract][Full Text] [Related]
10. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
[TBL] [Abstract][Full Text] [Related]
11. B cell targeted therapies: safety considerations.
Kavanaugh AF
J Rheumatol Suppl; 2006 May; 77():18-23. PubMed ID: 16652441
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
[TBL] [Abstract][Full Text] [Related]
13. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
14. What is the role of rituximab in the treatment of rheumatoid arthritis?
Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
16. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
Di W; Chang Y; Wu YJ; Wei W
Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
[TBL] [Abstract][Full Text] [Related]
17. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
Jacobi AM; Dörner T
Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
[TBL] [Abstract][Full Text] [Related]
18. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the treatment of rheumatoid arthritis.
Schuna AA
Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.
Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
